MiNK Therapeutics (INKT) Competitors $7.28 +0.12 (+1.60%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. GNLX, HURA, ANIX, PLX, PROC, CRDL, ATOS, QNTM, CCCC, and CRBPShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Genelux (GNLX), TuHURA Biosciences (HURA), Anixa Biosciences (ANIX), Protalix BioTherapeutics (PLX), Procaps Group (PROC), Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Quantum Biopharma (QNTM), C4 Therapeutics (CCCC), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Genelux TuHURA Biosciences Anixa Biosciences Protalix BioTherapeutics Procaps Group Cardiol Therapeutics Atossa Genetics Quantum Biopharma C4 Therapeutics Corbus Pharmaceuticals Genelux (NASDAQ:GNLX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings. Which has higher valuation & earnings, GNLX or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K11,001.21-$29.87M-$0.88-3.31MiNK TherapeuticsN/AN/A-$9.51M-$2.52-2.89 Which has more volatility & risk, GNLX or INKT? Genelux has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Do analysts prefer GNLX or INKT? Genelux currently has a consensus price target of $17.75, suggesting a potential upside of 508.92%. MiNK Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 414.76%. Given Genelux's stronger consensus rating and higher probable upside, equities analysts clearly believe Genelux is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GNLX or INKT? In the previous week, Genelux had 3 more articles in the media than MiNK Therapeutics. MarketBeat recorded 3 mentions for Genelux and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.89 beat Genelux's score of 0.76 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Genelux Positive MiNK Therapeutics Very Positive Do institutionals & insiders have more ownership in GNLX or INKT? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 9.3% of Genelux shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is GNLX or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -93.04% -74.17% MiNK Therapeutics N/A N/A -140.72% SummaryGenelux beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.07M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-2.8921.2326.5720.02Price / SalesN/A280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book-1.477.498.065.50Net Income-$9.51M-$55.05M$3.15B$248.50M7 Day Performance-2.54%2.58%1.72%2.61%1 Month Performance2.17%5.22%3.92%5.42%1 Year Performance-19.18%5.04%35.02%20.76% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics3.4324 of 5 stars$7.29+1.6%$37.50+414.8%-18.3%$29.07MN/A-2.8930Positive NewsGap DownGNLXGenelux1.7647 of 5 stars$2.77-6.7%$17.75+540.8%+66.1%$112.07M$10K-3.1510HURATuHURA Biosciences1.501 of 5 stars$2.53-0.8%$12.67+400.7%N/A$111.39MN/A0.00N/AAnalyst RevisionGap UpHigh Trading VolumeANIXAnixa Biosciences3.0488 of 5 stars$3.49+3.3%$9.00+157.9%+40.5%$108.87M$210K-9.185PLXProtalix BioTherapeutics2.8915 of 5 stars$1.35-3.6%$15.00+1,011.1%+33.3%$107.47M$59.76M-10.38200PROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCRDLCardiol Therapeutics2.5261 of 5 stars$1.28+3.2%$8.67+577.1%-29.1%$102.49MN/A-3.7620Positive NewsGap UpATOSAtossa Genetics2.1927 of 5 stars$0.80+1.3%$6.17+670.8%-27.8%$102.04MN/A-3.818Positive NewsQNTMQuantum BiopharmaN/A$23.01-34.3%N/AN/A$101.76MN/A-1.44N/ACCCCC4 Therapeutics2.0262 of 5 stars$1.47+3.5%$12.00+716.3%-66.4%$100.83M$35.58M-1.00150CRBPCorbus Pharmaceuticals3.9189 of 5 stars$7.89-4.2%$50.88+544.8%-83.9%$100.83MN/A-1.8740 Related Companies and Tools Related Companies Genelux Competitors TuHURA Biosciences Competitors Anixa Biosciences Competitors Protalix BioTherapeutics Competitors Procaps Group Competitors Cardiol Therapeutics Competitors Atossa Genetics Competitors Quantum Biopharma Competitors C4 Therapeutics Competitors Corbus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts